Critical role of the STAT3 pathway in the cardioprotective efficacy of zoniporide in a model of myocardial preservation - The rat isolated working heart

British Journal of Pharmacology

Volumn 162, Issue 3, 2011, Pages 633-647

  Gao, L ^a   Tsun, J ^a   Sun, L ^a,b   Kwan, J ^a   Watson, A ^a   MacDonald, P S ^a,c   Hicks, M ^c,d  

^a VICTOR CHANG CARDIAC RESEARCH INSTITUTE   (Australia)

^b KUNMING MEDICAL UNIVERSITY   (China)

^c ST VINCENT S HOSPITAL   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

ischemia reperfusion injury; myocardial preservation; sodium hydrogen exchange inhibitor; STAT3 pathway; zoniporide

Indexed keywords

CASPASE 3; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE 1; STAT3 PROTEIN; ZONIPORIDE;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME RELEASE; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PRESERVATION; HEART PROTECTION; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RAT; UPREGULATION;

ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR PHYSIOLOGICAL PROCESSES; CASPASE 3; CYCLIC S-OXIDES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANIDINES; HEART; HEART TRANSPLANTATION; L-LACTATE DEHYDROGENASE; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCARDIUM; NALOXONE; NARCOTIC ANTAGONISTS; PYRAZOLES; RATS; RATS, WISTAR; REPERFUSION INJURY; STAT3 TRANSCRIPTION FACTOR;

EID: 78651413378     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01071.x     Document Type: Article

References (62)

1. Alexander SPH, Mathie A, Peters JA, (2009). Guide to receptors and channels (GRAC). 4th edn. Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Allan LA, Morrice N, Brady S, Magee G, Pathak S, Clarke PR, (2003). Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol 5: 647-654.
3. Avkiran M, Marber MS, (2002). Na(+)/H(+) exchange inhibitors for cardioprotective therapy: progress, problems and prospects. J Am Coll Cardiol 39: 747-753.
4. Avkiran M, Gross G, Karmazyn M, Klein H, Murphy E, Ytrehus K, (2001). Na+/H+ exchange in ischemia, reperfusion and preconditioning. Cardiovasc Res 50: 162-166.
5. Boengler K, Buechert A, Heinen Y, Roeskes C, Hilfiker-Kleiner D, Heusch G, et al. (2008). Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res 102: 131-135.
6. Bolli R, Dawn B, Xuan YT, (2001). Emerging role of the JAK-STAT pathway as a mechanism of protection against ischemia/reperfusion injury. J Mol Cell Cardiol 33: 1893-1896.
7. Buerke U, Pruefer D, Carter JM, Russ M, Schlitt A, Prondzinsky R, et al. (2008). Sodium/hydrogen exchange inhibition with cariporide reduces leukocyte adhesion via P-selectin suppression during inflammation. Br J Pharmacol 153: 1678-1685.
8. Butler KL, Huffman LC, Koch SE, Hahn HS, Gwathmey JK, (2006). STAT-3 activation is necessary for ischemic preconditioning in hypertrophied myocardium. Am J Physiol Heart Circ Physiol 291: H797-H803.
9. Chakrabarti S, Hoque AN, Karmazyn M, (1997). A rapid ischemia-induced apoptosis in isolated rat hearts and its attenuation by the sodium-hydrogen exchange inhibitor HOE 642 (cariporide). J Mol Cell Cardiol 29: 3169-3174.
10. Chu W, Rothfuss J, Chu Y, Zhou D, Mach RH, (2009). Synthesis and in vitro evaluation of sulfonamide isatin Michael acceptors as small molecule inhibitors of caspase 6. J Med Chem 52: 2188-2191.
11. Clements-Jewery H, Sutherland FJ, Allen MC, Tracey WR, Avkiran M, (2004). Cardioprotective efficacy of zoniporide, a potent and selective inhibitor of Na+/H+ exchanger isoform 1, in an experimental model of cardiopulmonary bypass. Br J Pharmacol 142: 57-66.
12. Cropper JR, Hicks M, Ryan JB, Macdonald PS, (2003). Cardioprotection by cariporide after prolonged hypothermic storage of the isolated working rat heart. J Heart Lung Transplant 22: 929-936.
13. Erhardt P, Schremser EJ, Cooper GM, (1999). B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol 19: 5308-5315.
14. Fallouh HB, Kentish JC, Chambers DJ, (2009). Targeting for cardioplegia: arresting agents and their safety. Curr Opin Pharmacol 9: 220-226.
15. Fan WJ, Genade S, Genis A, Huisamen B, Lochner A, (2009). Dexamethasone-induced cardioprotection: a role for the phosphatase MKP-1? Life Sci 84: 838-846.
16. Fan WJ, van Vuuren D, Genade S, Lochner A, (2010). Kinases and phosphatases in ischaemic preconditioning: a re-evaluation. Basic Res Cardiol 105: 495-511.
17. Fuglesteg BN, Suleman N, Tiron C, Kanhema T, Lacerda L, Andreasen TV, et al. (2008). Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion. Basic Res Cardiol 103: 444-453.
18. Gao L, Hicks M, Macdonald PS, (2005). Improved preservation of the rat heart with celsior solution supplemented with cariporide plus glyceryl trinitrate. Am J Transplant 5: 1820-1826.
19. Garciarena CD, Caldiz CI, Correa MV, Schinella GR, Mosca SM, Chiappe de Cingolani GE, et al. (2008). Na+/H+ exchanger-1 inhibitors decrease myocardial superoxide production via direct mitochondrial action. J Appl Physiol 105: 1706-1713.
20. Goodman MD, Koch SE, Fuller-Bicer GA, Butler KL, (2008). Regulating RISK: a role for JAK-STAT signaling in postconditioning? Am J Physiol Heart Circ Physiol 295: H1649-H1656.
21. Gross ER, Hsu AK, Gross GJ, (2006). The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3 beta. Am J Physiol Heart Circ Physiol 291: H827-H834.
22. Haider KH, Idris NM, Kim HW, Ahmed RPH, Shujia J, Ashraf M, (2010). MicroRNA-21 is a key determinant in IL11/Stat3 anti-apoptotic signalling pathway in preconditioning of skeletal myoblasts. Cardiovasc Res 88: 168-178.
23. Hattori R, Maulik N, Otani H, Zhu L, Cordis G, Engelman RM, et al. (2001). Role of STAT3 in ischemic preconditioning. J Mol Cell Cardiol 33: 1929-1936.
24. Hausenloy DJ, Yellon DM, (2007). Preconditioning and postconditioning: united at reperfusion. Pharmacol Ther 116: 173-191.
25. Hicks M, Hing A, Gao L, Ryan J, Macdonald PS, (2006). Organ preservation. Methods Mol Biol 333: 331-374.
26. Hing AJ, Watson A, Hicks M, Gao L, Faddy SC, McMahon AC, et al. (2009). Combining cariporide with glyceryl trinitrate optimizes cardiac preservation during porcine heart transplantation. Am J Transplant 9: 2048-2056.
27. Javadov S, Choi A, Rajapurohitam V, Zeidan A, Basnakian AG, Karmazyn M, (2008). NHE-1 inhibition-induced cardioprotection against ischaemia/reperfusion is associated with attenuation of the mitochondrial permeability transition. Cardiovasc Res 77: 416-424.
28. Karmazyn M, (1988). Amiloride enhances postischemic ventricular recovery: possible role of Na+-H+ exchange. Am J Physiol 255: H608-H615.
29. Karmazyn M, (1999). The role of the myocardial sodium-hydrogen exchanger in mediating ischemic and reperfusion injury. From amiloride to cariporide. Ann N Y Acad Sci 874: 326-334.
30. Klein HH, Pich S, Bohle RM, Lindert-Heimberg S, Nebendahl K, (2000). Na(+)/H(+) exchange inhibitor cariporide attenuates cell injury predominantly during ischemia and not at onset of reperfusion in porcine hearts with low residual blood flow. Circulation 102: 1977-1982.
31. Knight DR, Smith AH, Flynn DM, MacAndrew JT, Ellery SS, Kong JX, et al. (2001). A novel sodium-hydrogen exchanger isoform-1 inhibitor, zoniporide, reduces ischemic myocardial injury in vitro and in vivo. J Pharmacol Exp Ther 297: 254-259.
32. Kwan J, Gao L, Macdonald PS, Hicks M, (2008). Protective effect of glyceryl trinitrate and cariporide in a model of donor heart preservation: activation of Erk1/2 pathway. Transplantation 86: 391.
33. Lacerda L, Somers S, Opie LH, Lecour S, (2009). Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc Res 84: 201-208.
34. Lecour S, (2009). Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway? J Mol Cell Cardiol 47: 32-40.
35. Marala RB, Brown JA, Kong JX, Tracey WR, Knight DR, Wester RT, et al. (2002). Zoniporide: a potent and highly selective inhibitor of human Na(+)/H(+) exchanger-1. Eur J Pharmacol 451: 37-41.
36. McMurray JS, (2006). A new small-molecule Stat3 inhibitor. Chem Biol 13: 1123-1124.
37. Menasche P, Termignon JL, Pradier F, Grousset C, Mouas C, Alberici G, et al. (1994). Experimental evaluation of Celsior, a new heart preservation solution. Eur J Cardiothorac Surg 8: 207-213.
38. Mentzer RM, Jr, Bartels C, Bolli R, Boyce S, Buckberg GD, Chaitman B, et al. (2008). Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study. Ann Thorac Surg 85: 1261-1270.
39. Miura T, Liu Y, Goto M, Tsuchida A, Miki T, Nakano A, et al. (2001). Mitochondrial ATP-sensitive K+ channels play a role in cardioprotection by Na+-H+ exchange inhibition against ischemia/reperfusion injury. J Am Coll Cardiol 37: 957-963.
40. Murphy E, Steenbergen C, (2008). Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 88: 581-609.
41. Negoro S, Kunisada K, Tone E, Funamoto M, Oh H, Kishimoto T, et al. (2000). Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction. Cardiovasc Res 47: 797-805.
42. Novosyadlyy R, Kurshan N, Lann D, Vijayakumar A, Yakar S, LeRoith D, (2008). Insulin-like growth factor-1 protects cells from ER stress-induced apoptosis via enhancement of the adaptive capacity of endoplasmic reticulum. Cell Death Differ 15: 1304-1317.
43. Otani H, Uchiyama T, Yamamura T, Nakao Y, Hattori R, Ninomiya H, et al. (2000). Effects of the Na+/H+ exchange inhibitor cariporide (HOE 642) on cardiac function and cardiomyocyte cell death in rat ischaemic-reperfused heart. Clin Exp Pharmacol Physiol 27: 387-393.
44. Pedersen SF, Darborg BV, Rasmussen M, Nylandsted J, Hoffmann EK, (2007a). The Na+/H+ exchanger, NHE1, differentially regulates mitogen-activated protein kinase subfamilies after osmotic shrinkage in Ehrlich Lettre Ascites cells. Cell Physiol Biochem 20: 735-750.
45. Pedersen SF, Darborg BV, Rentsch ML, Rasmussen M, (2007b). Regulation of mitogen-activated protein kinase pathways by the plasma membrane Na+/H+ exchanger, NHE1. Arch Biochem Biophys 462: 195-201.
46. Rentsch ML, Ossum CG, Hoffmann EK, Pedersen SF, (2007). Roles of Na+/H+ exchange in regulation of p38 mitogen-activated protein kinase activity and cell death after chemical anoxia in NIH3T3 fibroblasts. Pflugers Arch 454: 649-662.
47. Ruifrok AC, Johnston DA, (2001). Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 23: 291-299.
48. Rupprecht HJ, vom Dahl J, Terres W, Seyfarth KM, Richardt G, Schultheibeta HP, et al. (2000). Cardioprotective effects of the Na(+)/H(+) exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA. Circulation 101: 2902-2908.
49. Schust J, Sperl B, Hollis A, Mayer TU, Berg T, (2006). Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 13: 1235-1242.
50. Shipolini AR, Galinanes M, Edmondson SJ, Hearse DJ, Avkiran M, (1997). Na+/H+ exchanger inhibitor HOE-642 improves cardioplegic myocardial preservation under both normothermic and hypothermic conditions. Circulation 96: II-266-II-273.
51. Stromer H, de Groot MC, Horn M, Faul C, Leupold A, Morgan JP, et al. (2000). Na(+)/H(+) exchange inhibition with HOE642 improves postischemic recovery due to attenuation of Ca(2+) overload and prolonged acidosis on reperfusion. Circulation 101: 2749-2755.
52. Teshima Y, Akao M, Jones SP, Marban E, (2003). Cariporide (HOE642), a selective Na+-H+ exchange inhibitor, inhibits the mitochondrial death pathway. Circulation 108: 2275-2281.
53. Theroux P, Chaitman BR, Danchin N, Erhardt L, Meinertz T, Schroeder JS, et al. (2000). Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators. Circulation 102: 3032-3038.
54. Tracey WR, Allen MC, Frazier DE, Fossa AA, Johnson CG, Marala RB, et al. (2003). Zoniporide: a potent and selective inhibitor of the human sodium-hydrogen exchanger isoform 1 (NHE-1). Cardiovasc Drug Rev 21: 17-32.
55. Tritto FP, Inserte J, Garcia-Dorado D, Ruiz-Meana M, Soler-Soler J, (1998). Sodium/hydrogen exchanger inhibition reduces myocardial reperfusion edema after normothermic cardioplegia. J Thorac Cardiovasc Surg 115: 709-715.
56. Turkson J, Zhang S, Mora LB, Burns A, Sebti S, Jove R, (2005). A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem 280: 32979-32988.
57. Vignais ML, Sadowski HB, Watling D, Rogers NC, Gilman M, (1996). Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins. Mol Cell Biol 16: 1759-1769.
58. Wu KL, Khan S, Lakhe-Reddy S, Jarad G, Mukherjee A, Obejero-Paz CA, et al. (2004). The NHE1 Na+/H+ exchanger recruits ezrin/radixin/moesin proteins to regulate Akt-dependent cell survival. J Biol Chem 279: 26280-26286.
59. Xuan YT, Guo Y, Han H, Zhu Y, Bolli R, (2001). An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc Natl Acad Sci USA 98: 9050-9055.
60. Xue J, Zhou D, Yao H, Gavrialov O, McConnell MJ, Gelb BD, et al. (2007). Novel functional interaction between Na+/H+ exchanger 1 and tyrosine phosphatase SHP-2. Am J Physiol Regul Integr Comp Physiol 292: R2406-R2416.
61. You L, Li L, Xu Q, Ren J, Zhang F, (2010). Postconditioning reduces infarct size and cardiac myocyte apoptosis via the opioid receptor and JAK-STAT signaling pathway. Mol Biol Rep doi: 10.1007/s11033-010-0126-y.
62. Zatta AJ, Kin H, Yoshishige D, Jiang R, Wang N, Reeves JG, et al. (2008). Evidence that cardioprotection by postconditioning involves preservation of myocardial opioid content and selective opioid receptor activation. Am J Physiol Heart Circ Physiol 294: H1444-H1451.